If NanoSomiX Inc has a test that can truly predict

Quote:

---

If NanoSomiX Inc has a test that can truly predict a decade in advance at the specs they are reporting...Why in the world would they be interested in acquiring lympro?

---

It's the other way around. Amarantus is looking at acquiring other diagnostic asset(s) per what they said the last few months.

Keep in mind, I didn't say they Amarantus was interested in acquiring NanoSomiX, but it's likely they would acquire a small, very promising bio company like NanoSomiX as an example.

If Amarantus did acquire NanoSomiX, the irony is there would be a lot of bitching and moaning on all 3 message boards about what a dumb acquisition it was to purchase a company with products so far off in the future, more dilution to fund the research, no revenues, and a CEO Navy guy with a MBA and Engineering degree.


Dec. 22, 2014 - "Moving forward, we expect to announce additional significant news in the coming weeks regarding LymPro, as well as pending additions to our diagnostics division to buttress this business unit for a potential spin-off into a standalone entity."
Nov. 18, 2014 - AMBS Near-Term Milestone: Preparation for potential spin-out of diagnostics division (potential stock dividend to shareholders)
Oct. 27, 2014 - "We are actively evaluating additional complementary late-stage neurology-focused diagnostic assets that would bolster our diagnostic division and make for a successful ‘spin-out’ while concurrently returning value to our shareholders. We believe we will be able to execute on this strategy in the near-term."